SCHEMBL479743

SCHEMBL479743

Nc1ccc(CC=O)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.46
TSHR P16473 3/20 0.46
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
ALDH1A1 P00352 5/20 0.41
ALOX15 P16050 2/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
NFKB1 P19838 1/20 0.39
PMP22 Q01453 1/20 0.39
PDE7A Q13946 1/20 0.36
HTT P42858 4/20 0.36
IDO1 P14902 2/20 0.36
GAA P10253 2/20 0.35
TDP1 Q9NUW8 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3467784 0.86 CYP3A4 (0.48) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL15358717 0.81 CASP1 (0.39) CYP3A4TSHRALDH1A1ALOX15THRB
SCHEMBL9566566 0.80 ALDH1A1 (0.46) CYP3A4TSHRCA1ALDH1A1ALOX15
SCHEMBL11292182 0.80 CYP3A4 (0.46) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL7936360 0.80 CYP3A4 (0.46) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL29439097 0.79 IDO1 (0.54) CYP3A4HTTIDO1TDP1SMN1; SMN2
SCHEMBL895205 0.79 IDO1 (0.54) CYP3A4HTTIDO1TDP1SMN1; SMN2
SCHEMBL14744357 0.78 CSNK2A2 (0.47) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL3789087 0.77 CYP3A4 (0.52) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL31175763 0.76 CYP3A4 (0.56) CYP3A4TSHRCA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265088-A1 SREBP BLOCKERS FOR USE IN TREATING LIVER FIBROSIS, ELEVATED CHOLESTEROL AND INSULIN RESISTANCE Medivation Technologies LLC (US) 2018-01-10 EP disclosed
EP-3038622-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Medivation Technologies, Inc. (US) 2016-07-06 EP disclosed
WO-2015031650-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE CHAKRAVARTY SARVAJIT (US) 2015-03-05 WO disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
EP-2205562-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009040288-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed